Helen Sabzevari Sells 119,250 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) CEO Helen Sabzevari sold 119,250 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $519,930.00. Following the transaction, the chief executive officer owned 3,768,872 shares in the company, valued at approximately $16,432,281.92. The trade was a 3.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Stock Performance

NASDAQ PGEN opened at $3.86 on Wednesday. Precigen, Inc. has a 1 year low of $1.28 and a 1 year high of $5.47. The company has a debt-to-equity ratio of 4.62, a current ratio of 4.82 and a quick ratio of 4.12. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -3.27 and a beta of 1.06. The company has a fifty day moving average price of $4.04 and a 200-day moving average price of $4.10.

Precigen (NASDAQ:PGEN) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The firm had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. As a group, equities research analysts predict that Precigen, Inc. will post 0.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Citizens Jmp upped their target price on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. Wall Street Zen lowered shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. HC Wainwright upped their target price on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Finally, Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $12.50.

Hedge Funds Weigh In On Precigen

Several institutional investors have recently added to or reduced their stakes in the stock. State Street Corp grew its position in Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock valued at $45,248,000 after buying an additional 6,335,033 shares during the period. Geode Capital Management LLC grew its position in Precigen by 15.9% during the fourth quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company’s stock valued at $18,653,000 after buying an additional 613,340 shares during the period. Occam Crest Management LP grew its position in Precigen by 29.6% during the fourth quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after buying an additional 799,339 shares during the period. SymBiosis Capital Partners LLC bought a new position in Precigen during the fourth quarter valued at about $12,540,000. Finally, Bank of America Corp DE grew its position in Precigen by 201.1% during the third quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock valued at $8,245,000 after buying an additional 1,673,731 shares during the period. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.